BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 21486625)

  • 1. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
    Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
    Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS; Bhan AK; Pascual M; Thiim M; Benedict Cosimi A; Chung RT
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
    Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
    Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.
    Jain A; Demetris AJ; Manez R; Tsamanadas AC; Van Thiel D; Rakela J; Starzl TE; Fung JJ
    Liver Transpl Surg; 1998 May; 4(3):197-203. PubMed ID: 9563957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA; Lee VS; Wang E; Rinella ME; Levitsky J
    Transplant Proc; 2010 Nov; 42(9):3647-51. PubMed ID: 21094833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.
    Al Nahdi N; Ford JA; Greanya ED; Harrigan JA; Tse I; Steinbrecher UP; Erb SR; Yoshida EM
    Ann Hepatol; 2013; 12(1):156-60. PubMed ID: 23293209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
    Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
    J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
    Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
    Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
    Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
    J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
    Saab S; Jimenez M; Bau S; Goo T; Zhao D; Durazo F; Han S; El Kabany M; Kaldas F; Tong MJ; Busuttil RW
    Clin Transplant; 2015 Sep; 29(9):813-9. PubMed ID: 26147216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.